Cannabigerol (CBG) products and methods of use
AssigneeBazelet Health Systems, Inc.
InventorsMichael Elzufon, Howard Hoffberg
Life of this patent
Estimating the term…
Abstract
A cannabinoid composition, comprising a full spectrum extract of a plant of genus cannabis comprising at least 5% by weight cannabigerol, comprising cannabis terpenes and cannabis flavonoids, and substantially without cannabidiol and tetrahydrocannabinol. The composition may be a pharmaceutically acceptable formulation for oral, sublingual, inhaled, vaporized, or smoked administration. The formulation may include absorption or pharmacological enhancers e.g., curcumin, resveratrol, quercitin, piperine and/or N-alkylamides. The composition has anti-inflammatory properties beneficial as a prophylaxis or therapy of symptoms due to SARS-Cov2 infection.
Claims11
A capsule consisting essentially of:
- at least 5 mg of a cannabinoid selected from the group consisting of cannabigerol, cannabigerol acid, cannabigerovarin, and cannabigerovarin acid;
- at least 300 mg palmitoylethanolamide;
- and
- piperine and curcumin together in an amount sufficient to enhance oral absorption of the cannabinoid,
- wherein the capsule is substantially without cannabidiol and tetrahydrocannabinol.
A capsule consisting essentially of:
- at least 5 mg of cannabigerol acid;
- at least 300 mg palmitoylethanolamide;
- and
- piperine and curcumin together in an amount sufficient to enhance oral absorption of the cannabinoid,
- wherein the capsule is substantially without cannabidiol and tetrahydrocannabinol.
Dependencies are inferred from the claim text.